IP Library › Granted Patent US 12,247,026
Granted Patent B2
US 12,247,026 · App. 17/405,204 · Granted Mar 11, 2025

Heterocyclic compounds as immunomodulators

Inventors: Liangxing Wu (Wilmington, DE); Jingwei Li (Westfield, NJ); Wenqing Yao (Chadds Ford, PA)
Assignee: Incyte Corporation
C07D471/04A61P37/04C07D413/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,026
App. No.
17/405,204
Granted
Mar 11, 2025
Kind
B2
Abstract

Disclosed are compounds of Formula (I′), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Claims (135)

1. A method of treating cancer, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, colorectal cancer, cervical cancer, endometrial cancer, gastric cancer, esophageal cancer, cancers with high microsatellite instability (MST high ), biliary tract cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, cutaneous squamous cell carcinoma, hepatic cancer, melanoma, cancer of the bladder, cancer of the urethra, and renal cancer; said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and

(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl) piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

4. The method of claim 1 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

5. The method of claim 4 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid.

6. The method of claim 1 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

7. The method of claim 6 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid.

8. The method of claim 1 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

10. The method of claim 1 , wherein the compound is(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

11. The method of claim 10 , wherein the compound is(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

12. The method of claim 1 , wherein the cancer is lung cancer.

13. The method of claim 12 , wherein the lung cancer is small cell lung cancer.

14. The method of claim 12 , wherein the lung cancer is non-small cell lung cancer.

15. The method of claim 1 , wherein the cancer is hepatic cancer.

16. The method of claim 15 , wherein the hepatic cancer is hepatocellular carcinoma.

17. The method of claim 1 , wherein the cancer is melanoma.

18. The method of claim 1 , wherein the cancer is cancer of the bladder.

19. The method of claim 1 , wherein the cancer is cancer of the urethra.

20. The method of claim 1 , wherein the cancer is renal cancer.

21. The method of claim 20 , wherein the renal cancer is renal cell carcinoma.

22. A method of treating a tumor expressing PD-L1, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from:

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid,

(R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and

(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid,

or a pharmaceutically acceptable salt thereof,

the tumor expressing PD-L1 is selected from the group consisting of breast cancer, head and neck cancer, colorectal cancer, cervical cancer, endometrial cancer, stomach cancer, esophageal cancer, cancers with high microsatellite instability (MST high ), biliary tract cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, lung cancer, cutaneous squamous cell carcinoma, hepatic cancer, melanoma, cancer of the bladder, gastric cancer, cancer of the urethra, and renal cancer.

23. The method of claim 22 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

25. The method of claim 22 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

26. The method of claim 25 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid.

27. The method of claim 22 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

28. The method of claim 27 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-(((R)-3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)-3-methylpyrrolidine-3-carboxylic acid.

29. The method of claim 22 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

30. The method of claim 29 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

31. The method of claim 22 , wherein the compound is(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

32. The method of claim 31 , wherein the compound is(S)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxy-3-methylpyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid.

33. The method of claim 1 , wherein the cancer is cutaneous squamous cell carcinoma.

34. The method of claim 12 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

35. The method of claim 13 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

36. The method of claim 14 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

37. The method of claim 15 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

38. The method of claim 16 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

39. The method of claim 17 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

40. The method of claim 18 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

41. The method of claim 19 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

42. The method of claim 20 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

43. The method of claim 21 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

44. The method of claim 33 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

45. The method of claim 1 , wherein the cancer is breast cancer.

46. The method of claim 45 , wherein the breast cancer is triple-negative breast cancer (TNBC).

47. The method of claim 1 , wherein the cancer is head and neck cancer.

48. The method of claim 47 , wherein the head and neck cancer is squamous cell carcinoma of the head and neck.

49. The method of claim 1 , wherein the cancer is colorectal cancer.

50. The method of claim 1 , wherein the cancer is cervical cancer.

51. The method of claim 1 , wherein the cancer is endometrial cancer.

52. The method of claim 1 , wherein the cancer is gastric cancer.

53. The method of claim 1 , wherein the cancer is esophageal cancer.

54. The method of claim 1 , wherein the cancer is cancers with high microsatellite instability (MST high ).

55. The method of claim 18 , wherein the bladder cancer is nonmuscle invasive bladder cancer (NMIBC).

56. The method of claim 18 , wherein the bladder cancer is urothelial cancer.

57. The method of claim 1 , wherein the cancer is biliary tract cancer.

58. The method of claim 1 , wherein the cancer is Hodgkin's lymphoma.

59. The method of claim 1 , wherein the cancer is non-Hodgkin's lymphoma.

60. The method of claim 45 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

61. The method of claim 46 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

62. The method of claim 47 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

63. The method of claim 48 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

64. The method of claim 49 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

65. The method of claim 50 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

66. The method of claim 51 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

67. The method of claim 52 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

68. The method of claim 53 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

69. The method of claim 54 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

70. The method of claim 55 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

71. The method of claim 56 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

72. The method of claim 57 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

73. The method of claim 58 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

74. The method of claim 59 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

75. The method of claim 22 , wherein the cancer is lung cancer.

76. The method of claim 75 , wherein the lung cancer is small cell lung cancer.

77. The method of claim 75 , wherein the lung cancer is non-small cell lung cancer.

78. The method of claim 22 , wherein the cancer is hepatic cancer.

79. The method of claim 78 , wherein the hepatic cancer is hepatocellular carcinoma.

80. The method of claim 22 , wherein the cancer is melanoma.

81. The method of claim 22 , wherein the cancer is cancer of the bladder.

82. The method of claim 22 , wherein the cancer is cancer of the urethra.

83. The method of claim 22 , wherein the cancer is renal cancer.

84. The method of claim 83 , wherein the renal cancer is renal cell carcinoma.

85. The method of claim 22 , wherein the cancer is cutaneous squamous cell carcinoma.

86. The method of claim 22 , wherein the cancer is breast cancer.

87. The method of claim 86 , wherein the breast cancer is triple-negative breast cancer (TNBC).

88. The method of claim 22 , wherein the cancer is head and neck cancer.

89. The method of claim 88 , wherein the head and neck cancer is squamous cell carcinoma of the head and neck.

90. The method of claim 22 , wherein the cancer is colorectal cancer.

91. The method of claim 22 , wherein the cancer is cervical cancer.

92. The method of claim 22 , wherein the cancer is endometrial cancer.

93. The method of claim 22 , wherein the cancer is gastric cancer.

94. The method of claim 22 , wherein the cancer is esophageal cancer.

95. The method of claim 22 , wherein the cancer is cancers with high microsatellite instability (MST high ).

96. The method of claim 22 , wherein the cancer is biliary tract cancer.

97. The method of claim 22 , wherein the cancer is Hodgkin's lymphoma.

98. The method of claim 22 , wherein the cancer is non-Hodgkin's lymphoma.

99. The method of claim 75 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

100. The method of claim 76 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

101. The method of claim 77 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

102. The method of claim 78 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

103. The method of claim 79 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

104. The method of claim 80 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

105. The method of claim 81 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

106. The method of claim 82 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

107. The method of claim 83 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

108. The method of claim 84 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

109. The method of claim 85 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

110. The method of claim 86 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

111. The method of claim 87 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

112. The method of claim 88 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

113. The method of claim 89 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

114. The method of claim 90 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

115. The method of claim 91 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

116. The method of claim 92 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

117. The method of claim 93 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

118. The method of claim 94 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

119. The method of claim 95 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

120. The method of claim 96 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

121. The method of claim 97 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

122. The method of claim 98 , wherein the compound is (R)-1-((7-cyano-2-(3′-(2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-ylamino)-2,2′-dimethylbiphenyl-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2021
From: WU, LIANGXING; LI, JINGWEI; YAO, WENQING
To: INCYTE CORPORATION
Reel/Frame 057339/0653 →
Continuity (5)
Continuation 16856678 · Apr 23, 2020
Continuation 16369654 · Mar 29, 2019
Provisional Application 62687964 · Jun 21, 2018
Provisional Application 62650821 · Mar 30, 2018
Related Publication 20210380584A1 · Dec 9, 2021
References Cited (400)
US 3272781A · Goodrow · 1966 [cited by applicant]
US 4208328A · Lavallee et al. · 1980 [cited by applicant]
US 4789711A · Monnier et al. · 1988 [cited by applicant]
US 5077164A · Ueda et al. · 1991 [cited by applicant]
US 6114497A · Tada et al. · 2000 [cited by applicant]
US 6297351B1 · Murayama et al. · 2001 [cited by applicant]
US 6372907B1 · Lee et al. · 2002 [cited by applicant]
US 6521618B2 · Boschelli et al. · 2003 [cited by applicant]
US 6867200B1 · Allen et al. · 2005 [cited by applicant]
US 7320989B2 · Anderson et al. · 2008 [cited by applicant]
US 7417065B2 · Mi et al. · 2008 [cited by applicant]
US 7488802B2 · Collins et al. · 2009 [cited by applicant]
US 7491245B2 · Glenn et al. · 2009 [cited by applicant]
US 7691870B2 · Buchstaller et al. · 2010 [cited by applicant]
US 7851489B2 · Borzilleri et al. · 2010 [cited by applicant]
US 7906522B2 · Kishikawa et al. · 2011 [cited by applicant]
US 7943743B2 · Korman et al. · 2011 [cited by applicant]
US 8008449B2 · Korman et al. · 2011 [cited by applicant]
US 8163743B2 · Baldwin et al. · 2012 [cited by applicant]
US 8168757B2 · Finnefrock et al. · 2012 [cited by applicant]
US 8217149B2 · Irving et al. · 2012 [cited by applicant]
US 8541424B2 · DeGoey et al. · 2013 [cited by applicant]
US 8993604B2 · Byrd et al. · 2015 [cited by applicant]
US 9085576B2 · Minatti et al. · 2015 [cited by applicant]
US 9163017B2 · DeGoey et al. · 2015 [cited by applicant]
US 9394365B1 · Eisenbach-Schwartz et al. · 2016 [cited by applicant]
US 9540322B2 · Jorgensen et al. · 2017 [cited by applicant]
US 9603950B1 · Li et al. · 2017 [cited by applicant]
US 9611261B2 · Minatti et al. · 2017 [cited by applicant]
US 9643922B2 · Jorgensen et al. · 2017 [cited by applicant]
US 10017520B2 · Koehler et al. · 2018 [cited by applicant]
US 10202343B2 · Jorgensen et al. · 2019 [cited by applicant]
US 10308644B2 · Wu et al. · 2019 [cited by applicant]
US 10618916B2 · Wu et al. · 2020 [cited by applicant]
US 10669271B2 · Wu et al. · 2020 [cited by applicant]
US 10793565B2 · Wu et al. · 2020 [cited by applicant]
US 10800768B2 · Wu et al. · 2020 [cited by applicant]
US 10806785B2 · Liu et al. · 2020 [cited by applicant]
US 10906920B2 · Wu et al. · 2021 [cited by applicant]
US 11124511B2 · Wu et al. · 2021 [cited by applicant]
US 11339149B2 · Wu et al. · 2022 [cited by applicant]
US 11401279B2 · Li et al. · 2022 [cited by applicant]
US 11407749B2 · Wu et al. · 2022 [cited by applicant]
US 11414433B2 · Wu et al. · 2022 [cited by applicant]
US 11465981B2 · Wu et al. · 2022 [cited by applicant]
US 11535615B2 · Lajkiewicz et al. · 2022 [cited by applicant]
US 11566026B2 · Wu et al. · 2023 [cited by applicant]
US 11572366B2 · Li et al. · 2023 [cited by applicant]
US 11596692B1 · Wu et al. · 2023 [cited by applicant]
US 11608337B2 · Li et al. · 2023 [cited by applicant]
US 11613536B2 · Wu et al. · 2023 [cited by applicant]
US 11673883B2 · Lu et al. · 2023 [cited by applicant]
US 11718605B2 · Yu et al. · 2023 [cited by applicant]
US 11753406B2 · Jia et al. · 2023 [cited by applicant]
US 11760756B2 · Jia et al. · 2023 [cited by applicant]
US 11780836B2 · Zhou et al. · 2023 [cited by applicant]
US 11787793B2 · Wu et al. · 2023 [cited by applicant]
US 11866434B2 · Wang et al. · 2024 [cited by applicant]
US 11866435B2 · Lajkiewicz et al. · 2024 [cited by applicant]
US 11866451B2 · Jia et al. · 2024 [cited by applicant]
US 11879309B2 · Hope et al. · 2024 [cited by applicant]
US 12084443B2 · Zhou et al. · 2024 [cited by applicant]
US 20020082266A1 · Gallant et al. · 2002 [cited by applicant]
US 20030134843A1 · Lubisch et al. · 2003 [cited by applicant]
US 20030191115A1 · Pinto et al. · 2003 [cited by applicant]
US 20040018986A1 · Pitlik et al. · 2004 [cited by applicant]
US 20040058938A1 · Cullmann et al. · 2004 [cited by applicant]
US 20040063963A1 · Ueno et al. · 2004 [cited by applicant]
US 20040082635A1 · Hashimoto et al. · 2004 [cited by applicant]
US 20040186114A1 · Cirillo et al. · 2004 [cited by applicant]
US 20040214040A1 · Lee et al. · 2004 [cited by applicant]
US 20050187230A1 · Ding et al. · 2005 [cited by applicant]
US 20050245536A1 · Hao et al. · 2005 [cited by applicant]
US 20050260126A1 · Kudo et al. · 2005 [cited by applicant]
US 20050288295A1 · Currie et al. · 2005 [cited by applicant]
US 20060004010A1 · Habashita et al. · 2006 [cited by applicant]
US 20060084650A1 · Dong et al. · 2006 [cited by applicant]
US 20060089362A1 · Seno et al. · 2006 [cited by applicant]
US 20060178367A1 · Currie et al. · 2006 [cited by applicant]
US 20060183746A1 · Currie et al. · 2006 [cited by applicant]
US 20060229337A1 · Brittelli et al. · 2006 [cited by applicant]
US 20060270686A1 · Kelly et al. · 2006 [cited by applicant]
US 20070099938A1 · Ohmoto et al. · 2007 [cited by applicant]
US 20070191395A1 · Kawakami et al. · 2007 [cited by applicant]
US 20080045536A1 · Vaccaro et al. · 2008 [cited by applicant]
US 20080139557A1 · Blomgren et al. · 2008 [cited by applicant]
US 20080153834A1 · Blomgren et al. · 2008 [cited by applicant]
US 20080280891A1 · Kelly et al. · 2008 [cited by applicant]
US 20090163545A1 · Goldfarb · 2009 [cited by applicant]
US 20090253735A1 · Almario-Garcia et al. · 2009 [cited by applicant]
US 20090281075A1 · Roughton et al. · 2009 [cited by applicant]
US 20090281120A1 · Nakai et al. · 2009 [cited by applicant]
US 20090304821A1 · Notoya et al. · 2009 [cited by applicant]
US 20100155712A1 · Kitamura · 2010 [cited by applicant]
US 20100160292A1 · Whitney et al. · 2010 [cited by applicant]
US 20100160303A1 · Liu et al. · 2010 [cited by applicant]
US 20100249151A1 · Klein et al. · 2010 [cited by applicant]
US 20100267775A1 · Negoro et al. · 2010 [cited by applicant]
US 20100267778A1 · Kusuda et al. · 2010 [cited by applicant]
US 20100273832A1 · Jung et al. · 2010 [cited by applicant]
US 20100292227A1 · Yoakim et al. · 2010 [cited by applicant]
US 20110053915A1 · Ivaschenko et al. · 2011 [cited by applicant]
US 20110062858A1 · Yersin et al. · 2011 [cited by applicant]
US 20110065699A1 · De Peretti et al. · 2011 [cited by applicant]
US 20110065700A1 · De Peretti et al. · 2011 [cited by applicant]
US 20110065745A1 · De Peretti et al. · 2011 [cited by applicant]
US 20110124640A1 · Liu et al. · 2011 [cited by applicant]
US 20110294781A1 · Yamamoto et al. · 2011 [cited by applicant]
US 20110301145A1 · Barbosa Jr. et al. · 2011 [cited by applicant]
US 20120058996A1 · Liu et al. · 2012 [cited by applicant]
US 20120295884A1 · Altmann et al. · 2012 [cited by applicant]
US 20120323002A1 · Yamamoto et al. · 2012 [cited by applicant]
US 20120328569A1 · McComas et al. · 2012 [cited by applicant]
US 20130096118A1 · Liu et al. · 2013 [cited by applicant]
US 20130131063A1 · Castro et al. · 2013 [cited by applicant]
US 20130203741A1 · Suzuki et al. · 2013 [cited by applicant]
US 20130203747A1 · Yoakim et al. · 2013 [cited by applicant]
US 20130203754A1 · Yang et al. · 2013 [cited by applicant]
US 20130253011A1 · Jung et al. · 2013 [cited by applicant]
US 20140058097A1 · Kobayashi et al. · 2014 [cited by applicant]
US 20140088117A1 · Burch et al. · 2014 [cited by applicant]
US 20140107027A1 · Kong et al. · 2014 [cited by applicant]
US 20140128382A1 · Wu et al. · 2014 [cited by applicant]
US 20140243306A1 · Heng et al. · 2014 [cited by applicant]
US 20140275058A1 · Minatti et al. · 2014 [cited by applicant]
US 20140288094A1 · Bennett et al. · 2014 [cited by applicant]
US 20140378447A1 · Okano et al. · 2014 [cited by applicant]
US 20150005279A1 · Bonafoux et al. · 2015 [cited by applicant]
US 20150011751A1 · Kawakami et al. · 2015 [cited by applicant]
US 20150073024A1 · Sasikumar et al. · 2015 [cited by applicant]
US 20150181880A1 · Takahashi · 2015 [cited by applicant]
US 20150210680A1 · Kobayashi et al. · 2015 [cited by applicant]
US 20150232478A1 · Ishida et al. · 2015 [cited by applicant]
US 20150239868A1 · Pais et al. · 2015 [cited by applicant]
US 20150252011A1 · Minatti et al. · 2015 [cited by applicant]
US 20150258505A1 · Hironaka et al. · 2015 [cited by applicant]
US 20150291549A1 · Chupak et al. · 2015 [cited by applicant]
US 20150299227A1 · Wolkenberg et al. · 2015 [cited by applicant]
US 20150307465A1 · Scott et al. · 2015 [cited by applicant]
US 20150376172A1 · Guba et al. · 2015 [cited by applicant]
US 20160015690A1 · Babaoglu et al. · 2016 [cited by applicant]
US 20160046648A1 · Petrukhin et al. · 2016 [cited by applicant]
US 20160130251A1 · Graupe et al. · 2016 [cited by applicant]
US 20160194295A1 · Sasikumar et al. · 2016 [cited by applicant]
US 20160229816A1 · Sato et al. · 2016 [cited by applicant]
US 20160280695A1 · Minatti et al. · 2016 [cited by applicant]
US 20170107216A1 · Wu et al. · 2017 [cited by applicant]
US 20170145025A1 · Li et al. · 2017 [cited by applicant]
US 20170174671A1 · Wu et al. · 2017 [cited by applicant]
US 20170174679A1 · Lajkiewicz et al. · 2017 [cited by applicant]
US 20170304282A1 · Rocco et al. · 2017 [cited by applicant]
US 20170320875A1 · Li et al. · 2017 [cited by applicant]
US 20170342060A1 · Lu et al. · 2017 [cited by applicant]
US 20170362253A1 · Xiao et al. · 2017 [cited by applicant]
US 20180016260A1 · Yu et al. · 2018 [cited by applicant]
US 20180057486A1 · Wu et al. · 2018 [cited by applicant]
US 20180177784A1 · Wu et al. · 2018 [cited by applicant]
US 20180177870A1 · Liu et al. · 2018 [cited by applicant]
US 20180179179A1 · Wu et al. · 2018 [cited by applicant]
US 20180179197A1 · Wu et al. · 2018 [cited by applicant]
US 20180179201A1 · Wu et al. · 2018 [cited by applicant]
US 20180179202A1 · Wu et al. · 2018 [cited by applicant]
US 20180273519A1 · Wu et al. · 2018 [cited by applicant]
US 20190040082A1 · Xiao et al. · 2019 [cited by applicant]
US 20190062345A1 · Xiao et al. · 2019 [cited by applicant]
US 20190071439A1 · Li et al. · 2019 [cited by applicant]
US 20190144439A1 · Wu et al. · 2019 [cited by applicant]
US 20190202824A1 · Wu et al. · 2019 [cited by applicant]
US 20190225601A1 · Wu et al. · 2019 [cited by applicant]
US 20190270706A1 · Jorgensen et al. · 2019 [cited by applicant]
US 20190300524A1 · Wu et al. · 2019 [cited by applicant]
US 20190345170A1 · Wu et al. · 2019 [cited by applicant]
US 20200172533A1 · Wu et al. · 2020 [cited by applicant]
US 20200172541A1 · Li et al. · 2020 [cited by applicant]
US 20200181126A1 · Lu et al. · 2020 [cited by applicant]
US 20200255424A1 · Wu et al. · 2020 [cited by applicant]
US 20200277309A1 · Wu et al. · 2020 [cited by applicant]
US 20200283423A1 · Yu et al. · 2020 [cited by applicant]
US 20200325115A1 · Wu et al. · 2020 [cited by applicant]
US 20200397893A1 · Liu et al. · 2020 [cited by applicant]
US 20200407357A1 · Lajkiewicz et al. · 2020 [cited by applicant]
US 20210002276A1 · Wu et al. · 2021 [cited by applicant]
US 20210017164A1 · Lu et al. · 2021 [cited by applicant]
US 20210017175A1 · Li et al. · 2021 [cited by applicant]
US 20210040090A1 · Jia et al. · 2021 [cited by applicant]
US 20210094976A1 · Li et al. · 2021 [cited by applicant]
US 20210107900A1 · Wu et al. · 2021 [cited by applicant]
US 20210115025A1 · Yu et al. · 2021 [cited by applicant]
US 20210115068A1 · Wu et al. · 2021 [cited by applicant]
US 20210139511A1 · Jia et al. · 2021 [cited by applicant]
US 20210221819A1 · Li et al. · 2021 [cited by applicant]
US 20210317139A1 · Xiao et al. · 2021 [cited by applicant]
US 20210347771A1 · Wu et al. · 2021 [cited by applicant]
US 20210363137A1 · Wu et al. · 2021 [cited by applicant]
US 20220089588A1 · Wu et al. · 2022 [cited by applicant]
US 20220144830A1 · Zhou et al. · 2022 [cited by applicant]
US 20220144831A1 · Wang et al. · 2022 [cited by applicant]
US 20220144832A1 · Jia et al. · 2022 [cited by applicant]
US 20220193050A1 · Yang et al. · 2022 [cited by applicant]
US 20220194931A1 · Wu et al. · 2022 [cited by applicant]
US 20220213090A1 · Wu et al. · 2022 [cited by applicant]
US 20220340600A1 · Li et al. · 2022 [cited by applicant]
US 20220348594A1 · Wu et al. · 2022 [cited by applicant]
US 20220412976A1 · Lovat · 2022 [cited by applicant]
US 20230100875A1 · Lajkiewicz et al. · 2023 [cited by applicant]
US 20230146129A1 · Wu et al. · 2023 [cited by applicant]
US 20230149409A1 · Geschwindt · 2023 [cited by examiner]
US 20230181605A1 · Mohanlal et al. · 2023 [cited by applicant]
US 20230192689A1 · Lajkiewicz et al. · 2023 [cited by applicant]
US 20230226062A1 · Wu et al. · 2023 [cited by applicant]
US 20230406852A1 · Zhou et al. · 2023 [cited by applicant]
US 20240132523A1 · Jia et al. · 2024 [cited by applicant]
US 20240158395A1 · Wang et al. · 2024 [cited by applicant]
CA 2355249 · 2000 [cited by applicant]
CA 3099994 · 2019 [cited by applicant]
CL 2018001531 · 2018 [cited by applicant]
CL 2018003734 · 2019 [cited by applicant]
CL 2018003701 · 2019 [cited by applicant]
CL 2018003697 · 2019 [cited by applicant]
CL 2019001744 · 2019 [cited by applicant]
CL 2020002511 · 2020 [cited by applicant]
CN 1344256 · 2002 [cited by applicant]
CN 101891895 · 2010 [cited by applicant]
CN 101910158 · 2010 [cited by applicant]
CN 101993415 · 2011 [cited by applicant]
CN 103933036 · 2014 [cited by applicant]
CN 104045552 · 2014 [cited by applicant]
CN 104211726 · 2014 [cited by applicant]
CN 105073747 · 2015 [cited by applicant]
CN 105164121 · 2015 [cited by applicant]
CN 105705489 · 2016 [cited by applicant]
EP 0361069 · 1990 [cited by applicant]
EP 0644460 · 1995 [cited by applicant]
EP 1505068 · 2005 [cited by applicant]
EP 1644370 · 2006 [cited by applicant]
EP 1942105 · 2008 [cited by applicant]
EP 2233474 · 2010 [cited by applicant]
EP 2402345 · 2012 [cited by applicant]
EP 2871179 · 2015 [cited by applicant]
EP 2824099 · 2018 [cited by applicant]
FR 1425700 · 1966 [cited by applicant]
JP H10316853 · 1998 [cited by applicant]
JP 2000128986 · 2000 [cited by applicant]
JP 2000128987 · 2000 [cited by applicant]
JP 2000212281 · 2000 [cited by applicant]
JP 2001114893 · 2001 [cited by applicant]
JP 2001163975 · 2001 [cited by applicant]
JP 3461397 · 2003 [cited by applicant]
JP 2003287634 · 2003 [cited by applicant]
JP 2004059761 · 2004 [cited by applicant]
JP 2004091369 · 2004 [cited by applicant]
JP 2004294556 · 2004 [cited by applicant]
JP 2005002330 · 2005 [cited by applicant]
JP 2005248082 · 2005 [cited by applicant]
JP 2005290301 · 2005 [cited by applicant]
JP 2006290883 · 2006 [cited by applicant]
JP 2008218327 · 2008 [cited by applicant]
JP 2010202530 · 2010 [cited by applicant]
JP 2010540452 · 2010 [cited by applicant]
JP 2013084945 · 2013 [cited by applicant]
JP 2014520866 · 2014 [cited by applicant]
JP 2014532066 · 2014 [cited by applicant]
JP 2015155397 · 2015 [cited by applicant]
JP 2015193612 · 2015 [cited by applicant]
JP 2016135778 · 2016 [cited by applicant]
JP 2016532710 · 2016 [cited by applicant]
JP 2019523231 · 2019 [cited by applicant]
JP 2019530732 · 2019 [cited by applicant]
JP 2020504737 · 2020 [cited by applicant]
JP 2020504739 · 2020 [cited by applicant]
JP 2020514271 · 2020 [cited by applicant]
JP 2020514272 · 2020 [cited by applicant]
JP 6911031 · 2021 [cited by applicant]
JP 2015510890 · 2024 [cited by applicant]
KR 1715090 · 2015 [cited by applicant]
KR 1717601 · 2015 [cited by applicant]
KR 1653560 · 2016 [cited by applicant]
MX 2019007651 · 2020 [cited by applicant]
TW 103143948 · 2014 [cited by applicant]
TW 201625527 · 2016 [cited by applicant]
WO WO9827108 · 1998 [cited by applicant]
WO WO1999018096 · 1999 [cited by applicant]
WO WO9944992A1 · 1999 [cited by applicant]
WO WO0035886 · 2000 [cited by applicant]
WO WO0107409 · 2001 [cited by applicant]
WO WO2001047883 · 2001 [cited by applicant]
WO WO0174815 · 2001 [cited by applicant]
WO WO2002000196 · 2002 [cited by applicant]
WO WO0214321 · 2002 [cited by applicant]
WO WO0248147 · 2002 [cited by applicant]
WO WO02066477 · 2002 [cited by applicant]
WO WO02071827 · 2002 [cited by applicant]
WO WO02078700 · 2002 [cited by applicant]
WO WO02083672 · 2002 [cited by applicant]
WO WO02088124 · 2002 [cited by applicant]
WO WO03022845 · 2003 [cited by applicant]
WO WO03030901 · 2003 [cited by applicant]
WO WO03031587 · 2003 [cited by applicant]
WO WO2003042402 · 2003 [cited by applicant]
WO WO2004006906 · 2004 [cited by applicant]
WO WO2004033454 · 2004 [cited by applicant]
WO WO2004035588 · 2004 [cited by applicant]
WO WO2004085385 · 2004 [cited by applicant]
WO WO2004089940 · 2004 [cited by applicant]
WO WO2005000833 · 2005 [cited by applicant]
WO WO2005005429 · 2005 [cited by applicant]
WO WO2005014543 · 2005 [cited by applicant]
WO WO2005014599 · 2005 [cited by applicant]
WO WO2005023761 · 2005 [cited by applicant]
WO WO2005034869 · 2005 [cited by applicant]
WO WO2005047290 · 2005 [cited by applicant]
WO WO2005063710 · 2005 [cited by applicant]
WO WO2005077948 · 2005 [cited by applicant]
WO WO2005079802 · 2005 [cited by applicant]
WO WO2005080316 · 2005 [cited by applicant]
WO WO2005086808 · 2005 [cited by applicant]
WO WO2005086904 · 2005 [cited by applicant]
WO WO2005097751 · 2005 [cited by applicant]
WO WO2005103022 · 2005 [cited by applicant]
WO WO2005105798 · 2005 [cited by applicant]
WO WO2006034317 · 2006 [cited by applicant]
WO WO2006034337 · 2006 [cited by applicant]
WO WO2006050803 · 2006 [cited by applicant]
WO WO2006053121 · 2006 [cited by applicant]
WO WO2006094235 · 2006 [cited by applicant]
WO WO2006099075 · 2006 [cited by applicant]
WO WO2006125101 · 2006 [cited by applicant]
WO WO2007004954 · 2007 [cited by applicant]
WO WO2007034282 · 2007 [cited by applicant]
WO WO2007038314 · 2007 [cited by applicant]
WO WO2007061764 · 2007 [cited by applicant]
WO WO2007067711 · 2007 [cited by applicant]
WO WO2007069565 · 2007 [cited by applicant]
WO WO2007096764 · 2007 [cited by applicant]
WO WO2007113226 · 2007 [cited by applicant]
WO WO2007146712 · 2007 [cited by applicant]
WO WO2008011560 · 2008 [cited by applicant]
WO WO2008021745 · 2008 [cited by applicant]
WO WO2008027812 · 2008 [cited by applicant]
WO WO2008032171 · 2008 [cited by applicant]
WO WO2008033854 · 2008 [cited by applicant]
WO WO2008033857 · 2008 [cited by applicant]
WO WO2008033858 · 2008 [cited by applicant]
WO WO2008057254 · 2008 [cited by applicant]
WO WO2008062182 · 2008 [cited by applicant]
WO WO2008064317 · 2008 [cited by applicant]
WO WO2008064318 · 2008 [cited by applicant]
WO WO2008071944 · 2008 [cited by applicant]
WO WO2008079965 · 2008 [cited by applicant]
WO WO2008104077 · 2008 [cited by applicant]
WO WO2008104278 · 2008 [cited by applicant]
WO WO2008104279 · 2008 [cited by applicant]
WO WO2008111299 · 2008 [cited by applicant]
WO WO2008114002 · 2008 [cited by applicant]
WO WO2008118122 · 2008 [cited by applicant]
WO WO2008133274 · 2008 [cited by applicant]
WO WO2008134553 · 2008 [cited by applicant]
WO WO2008141249 · 2008 [cited by applicant]
WO WO2008156712 · 2008 [cited by applicant]
WO WO2009027733 · 2009 [cited by applicant]
WO WO2009038759 · 2009 [cited by applicant]
WO WO2009039397 · 2009 [cited by applicant]
WO WO2009059162 · 2009 [cited by applicant]
WO WO2009062059 · 2009 [cited by applicant]
WO WO2009075830 · 2009 [cited by applicant]
WO WO2009077197 · 2009 [cited by applicant]
WO WO2009079683 · 2009 [cited by applicant]
WO WO2009106539 · 2009 [cited by applicant]
WO WO2009106597 · 2009 [cited by applicant]
WO WO2009123986 · 2009 [cited by applicant]
WO WO2009139576 · 2009 [cited by applicant]
WO WO2009143156 · 2009 [cited by applicant]
WO WO2009146358 · 2009 [cited by applicant]
WO WO2010011837 · 2010 [cited by applicant]
WO WO2010029950 · 2010 [cited by applicant]
WO WO2010036959 · 2010 [cited by applicant]
WO WO2010056875 · 2010 [cited by applicant]
WO WO2010064020 · 2010 [cited by applicant]
WO WO2010071885 · 2010 [cited by applicant]
WO WO2010075376 · 2010 [cited by applicant]
WO WO2010080474 · 2010 [cited by applicant]
WO WO2010089411 · 2010 [cited by applicant]
WO WO2010104306 · 2010 [cited by applicant]
WO WO2010115736 · 2010 [cited by applicant]
WO WO2010119264 · 2010 [cited by applicant]
WO WO2010130034 · 2010 [cited by applicant]
WO WO2011002635 · 2011 [cited by applicant]
WO WO2011008709 · 2011 [cited by applicant]
WO WO2011018170 · 2011 [cited by applicant]
WO WO2011044181 · 2011 [cited by applicant]
WO WO2011047129 · 2011 [cited by applicant]
WO WO2011047319 · 2011 [cited by applicant]
WO WO2011050245 · 2011 [cited by applicant]
WO WO2009096202 · 2011 [cited by applicant]
WO WO2011066342 · 2011 [cited by applicant]
WO WO2011082400 · 2011 [cited by applicant]
WO WO2011097607 · 2011 [cited by applicant]
WO WO2011113606 · 2011 [cited by applicant]
WO WO2011117264 · 2011 [cited by applicant]
WO WO2011140202 · 2011 [cited by applicant]
Cited By (3)
US 12,404,272 US 12,466,822 US 12,516,044